Progress in the Research of PI3K/AKT/mTOR Pathway in Ovarian Clear Cell Carcinoma
AN Wen
TANG Xiao-han
LI Meng
DENG Suo
LU Mei-song
Abstract：Ovarian clear cell carcinoma (OCCC) is a special histological subtype of epithelial ovarian cancer, and presents resistant to the traditional chemotherapy on-hand, resulting in poor prognosis, so looking for a novel targeted therapy is extremely urgent. PI3K/AKT/mTOR pathway plays a significant role in the process of occurrence and development of ovarian cancer, and is intimately related to the resistance of chemotherapy. The suppression of apoptosis, the promotion of cell proliferation and the migration of tumor can be enforced by the pathway activation. The various proteins in PI3K/AKT/mTOR pathways express anomaly in the OCCC frequently, and thus the special receptor and kinase of the pathway could be a potential target for the therapy of ovarian clear cell carcinoma. The increasing of paclitaxel or cis-platinum cytotoxic effection and the growth of OCCC are in touch with PI3K/AKT/mTOR pathways in available studies. As the most frequent mutation in OCCC, ARID1A is especially related to PI3K/AKT/mTOR pathways. Therefore, to search for novel targeted drug to the pathway may benefit the treatment of OCCC to some extent. To lay a theory fundation of the new targeted treatment, the relationship of this pathway and OCCC will be interpreted in this paper.
Keywords：Ovarian neoplasms1-phosphatidylinositol 3-kinaseProtein kinasesSignal transductionTherapy
Publication Date：2015-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 564-567 )